FTC Punts Probe of PBMs but Could Take Up Issue Again

The Federal Trade Commission (FTC) won’t investigate PBMs’ business practices, despite considering a probe in a Feb. 17 meeting. The FTC’s four commissioners deadlocked 2-2 on a party line vote authorizing an investigation, with the two Democratic commissioners voting in favor of an investigation and the two Republicans voting against it.

During the meeting, according to a transcript prepared by the agency, FTC Chair Lina Khan, a Democrat, proposed “the use of the commission’s investigative authority under section 6B of the FTC Act to issue orders to large pharmacy benefit managers, to study a range of their commercial practices, to give us better insight into their drug pricing practices and their contracts with pharmacies, including for the purpose of examining whether those contracts negatively impact independent or unaffiliated pharmacies over recent decades.”

© 2024 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
March 14

News Briefs: Wegovy Gains Another Indication

READ MORE
iv-drip
March 14

PBMs Place Biosimilars on Preferred Tiers, yet Adoption Varies by Product

READ MORE
conference-presenter
March 14

AHIP Panelists: Accelerated Approval, IRA Uncertainty Worry Health Plans

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today